IP Library Granted Patent US 7,271,311
Granted Patent B2
US 7,271,311 · App. 10/252,111 · Granted Sep 18, 2007

Mammalian model for diabetes

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,271,311
App. No.
10/252,111
Granted
Sep 18, 2007
Kind
B2
Abstract

An object of the present invention is to provide a model mammal for diabetes onset, being useful for elucidating the onset mechanism of diabetes caused by a blockage of signal transduction from insulin, and for the development of a remedy for said diabetes, and to provide a screening method of a remedy for said diabetes. A diabetic-prone transgenic mouse is prepared in a process comprising the steps of: a transgene that contains a Meg1/Grb10 gene, an imprinted gene exhibiting maternal expression, or a human GRB10 gene in the downstream of a chicken β-actin promoter and in the upstream of a rabbit β-globin poly A is constructed, and subsequently the transgene is microinjected into a male proneucleus of a mouse fertilized egg; thus obtained egg cell is cultured and then transplanted into an oviduct of a pseudopregnant female mouse; after rearing up the recipient animal, baby mice that have the above-mentioned cDNA are selected from the mice born from the recipient animal.

Claims (7)

1. A transgenic mouse comprising a Meg 1/Grb10 transgene encoding a protein comprising the amino acid sequence set forth in SEQ ID NO:2, wherein said mouse exhibits glucosuria and/or hyperglycemia.

2. The transgenic mouse according to claim 1 , wherein the Meg1/Grb10 gene is a mouse Meg1/Grb10 gene comprising the DNA sequence set forth in SEQ ID NO:1.

3. The transgenic mouse according claim 1 , wherein the transgene contains a chicken β-actin promoter, the Meg1/Grb10 gene and a rabbit β-globin poly A signal, which are sequenced in the order as recited.

4. The transgenic mouse according to claim 3 , wherein the transgene containing a chicken β-actin promoter, the Meg1/Grb10 gene and a rabbit β-globin poly A signal, which are sequenced in this order, is the DNA sequence set forth in SEQ ID NO:3.

5. A method of generating a transgenic mouse characterized in comprising the steps of: (a) constructing a transgene containing cDNA that encodes a Meg1/Grb10 protein comprising SEQ ID NO: 2 downstream of a chicken β-actin promoter and upstream of a rabbit β-globin poly A signal, and subsequently microinjecting the transgene into a male pronucleus of a mouse fertilized egg; (b) culturing the egg cell microinjected with the transgene and then transplanting the cultured egg cell into an oviduct of a pseudopregnant female mouse; and (c) selecting baby mice comprising the transgene from mice born from the recipient female mouse produced in (b).

6. The method according to claim 5 , wherein the transgene comprises the DNA sequence set forth as SEQ ID NO: 3.

7. A screening method of a remedy for diabetes characterized in using a meg1/grb10 gene, wherein the transgenic mouse according to claim 1 is used and wherein a subject material is administered to the transgenic mouse and the level of glucose in urine and/or blood obtained from the transgenic mouse is measured.

Assignments (1)
CHANGE OF NAME Recorded Dec 16, 2005
From: JAPAN SCIENCE AND TECHNOLOGY CORPORATION
To: JAPAN SCIENCE AND TECHNOLOGY AGENCY
Reel/Frame 017400/0615 →